{Reference Type}: Journal Article
{Title}: Nonoperative management and local excision after neoadjuvant chemoradiation therapy for rectal cancer.
{Author}: Rizzo G;Amodio LE;D'Annibale G;Marzi F;Quero G;Menghi R;Tondolo V;
{Journal}: Minerva Surg
{Volume}: 79
{Issue}: 4
{Year}: 2024 Aug
暂无{DOI}: 10.23736/S2724-5691.24.10445-5
{Abstract}: Locally advanced extraperitoneal rectal cancer represents a significant clinical challenge, and currently, the standard treatment is based on neoadjuvant chemoradiation therapy (CRT) followed by radical surgical resection with total mesorectal excision (TME). In the last 30 years, its management has undergone significant changes due to the improvement of complementary radio- and chemotherapy treatments, the improvement of minimally invasive surgical approaches and the diffusion of organ-sparing approaches, such as nonoperative management, commonly called "watch and wait" (NOM) and local excision (LE), in highly selected patients who achieve a major or complete response to neoadjuvant CRT. This review aimed to critically examine the efficacy and oncological safety of NOM and LE compared to those of standard TME in rectal cancer patients after neoadjuvant CRT. Both the pros and cons of these approaches were strictly analyzed, providing a comprehensive and critical overview of these novel management strategies for rectal cancer.